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Background: Heart failure (HF) management involves multiple medications with resultant polypharmacy. There is little guidance on the safety 
and impact on clinical outcomes of stopping HF medications. The aim of this study was to evaluate and synthesise evidence regarding studies of 
medication withdrawal in patients with heart failure.
Methods: Comprehensive systematic search of the medical literature for prospective studies of withdrawal of drug therapy in patients with stable 
chronic systolic HF.
Results: Thirty-one studies met inclusion criteria. Four trials (251 subjects) of ACE inhibitor withdrawal showed deterioration in exercise tolerance 
and echocardiographic parameters. Six studies (148 subjects) of beta blocker (BB) withdrawal showed deterioration in left ventricular ejection 
fraction (LVEF) and clinical status. Long-term outcomes were variable. Meta-analysis of seven studies of digoxin withdrawal (in a total of 2987 
participants) prior to use of BB as standard of care, showed increased HF hospitalisations (risk ratio 1.32, 95% confidence interval 1.17, 1.48 
p<0.001), but no impact on mortality (RR 1.00, 95% CI 0.90-1.11, p=NS) and no reduction in all-cause hospitalisation (RR 1.03, 95% CI 0.98, 1.10, 
p=NS). Six studies (102 subjects) on vasodilator withdrawal showed variable hemodynamic rebound with clinical deterioration observed in a small 
number. Six studies (126 subjects) of inotropic agent introduction and then withdrawal in general showed return to baseline hemodynamic and 
exercise parameters. There were no trials of withdrawal of angiotensin II receptor blockers, aldosterone antagonists, amiodarone or aspirin.
Conclusion: Studies of medication withdrawal in stable chronic HF are generally small and most occurred prior to the introduction of ACE 
inhibitors and BB as standard care. Withdrawal of therapies with proven mortality benefit was associated with worsening of outcomes associated 
with HF. Therapies without mortality benefit did not show severe deterioration in HF status. No withdrawal studies exist for a number of medications 
used in HF patients.
